IDBS and Alchemi partner to accelerate biopharma regulatory filings with compliant AI agents
IDBS and Alchemi partner to combine compliant AI agents with governed biopharma data for faster regulatory submissions
16 Jun 2026
IDBS and Alchemi have announced a partnership connecting AI agents to data captured and contextualized in the IDBS Polar platform across the drug development lifecycle.
Preparing regulatory filings remains one of biopharma’s most persistent bottlenecks. Chemistry, manufacturing, and controls (CMC) teams spend months assembling data, drafting reports and reconstructing process histories, while current AI tools often break the compliance chain by pulling data out of validated systems.
Connecting Alchemi’s purpose-built agents to Polar’s trusted, AI-ready data foundation keeps validated data traceable and auditable. CMC technical reports, clinical study reports and submission dossiers can be drafted faster and routed through human-in-the-loop workflows for review and sign-off, maintaining compliance. According to Alchemi, in customer deployments across biopharma, teams have produced documents of this type up to 70% faster using its agents.
IDBS Polar powers the Lab Loop — from experiment execution, through data aggregation, to insights that drive decisions. By capturing structured, contextualized data at the point of creation within a single governed backbone, Polar delivers the data foundation that makes agentic AI viable in regulated environments.
Alchemi’s agents draw on Polar’s governed data to draft these reports and dossiers, then route each draft to a scientist for review and sign-off. Each human and AI action is captured in a 21 CFR Part 11 audit trail, so the work stays compliant from source to submission.
AI agents are only as good as the data they act on. This partnership ensures biopharma teams get both: governed data from Polar and purpose-built intelligence from Alchemi.
“A regulatory filing that takes a team weeks, our agents draft in minutes, at submission-ready quality, with the compliance trail intact, because they work straight from governed data in Polar. That’s the difference between AI you can demo and AI you can take to submission,” said Anuj Chadha, Co-Founder, Alchemi.
“Our mission is to accelerate life-changing therapies to patients, and as part of Danaher, that means turning ideas into impact with speed and certainty. IDBS delivers a governed data backbone that makes AI-ready data available across the biopharma lifecycle. By partnering with Alchemi, we can accelerate critical regulatory milestones using high-quality, compliant AI agents,” said Pietro Forgione, General Manager, IDBS.
Want the latest science news straight to your inbox? Become a SelectScience member for free today>>
Related products
Request Quote for All Products
IDBS Polar
IDBSIDBS Polar is a next-generation enterprise lab informatics platform that unifies ELN, LIMS, and LES capabilities into a single powerful data management system, purpose-built for both GxP-regulated and non-regulated laboratory environments.
Frequently asked questions
How does the IDBS and Alchemi partnership accelerate regulatory filings in biopharma?
The partnership connects Alchemi’s applied AI agents to governed, AI-ready data in the IDBS Polar platform across the drug development lifecycle. By drafting CMC technical reports, clinical study reports and submission dossiers directly from validated Polar data, teams can produce documents up to 70% faster while maintaining traceability, auditability and compliance for regulatory submissions.
What role does the IDBS Polar platform play in enabling compliant AI for drug development?
IDBS Polar powers the Lab Loop, capturing structured, contextualized data at the point of creation within a single governed backbone. This AI-ready data foundation enables agentic AI in regulated environments. Alchemi’s agents use Polar’s governed data to draft regulatory documents, while every human and AI action is recorded in a 21 CFR Part 11 audit trail, keeping work compliant from source to submission.
How do Alchemi’s AI agents improve CMC and clinical documentation for pharma and biotech teams?
Alchemi’s purpose-built AI agents generate CMC technical reports, clinical study reports and submission dossiers in minutes instead of weeks by working directly from IDBS Polar’s validated data. Drafts are routed through human-in-the-loop workflows for review and sign-off, preserving the compliance chain. According to Alchemi, biopharma teams have produced these regulatory documents up to 70% faster using its agents.